| Literature DB >> 29741576 |
Katherine L Anders1, Zoe Cutcher1, Immo Kleinschmidt2,3, Christl A Donnelly4, Neil M Ferguson4, Citra Indriani5,6, Peter A Ryan1, Scott L O'Neill1, Nicholas P Jewell7, Cameron P Simmons1.
Abstract
Cluster-randomized controlled trials are the gold standard for assessing efficacy of community-level interventions, such as vector-control strategies against dengue. We describe a novel cluster-randomized trial methodology with a test-negative design (CR-TND), which offers advantages over traditional approaches. This method uses outcome-based sampling of patients presenting with a syndrome consistent with the disease of interest, who are subsequently classified as test-positive cases or test-negative controls on the basis of diagnostic testing. We used simulations of a cluster trial to demonstrate validity of efficacy estimates under the test-negative approach. We demonstrated that, provided study arms are balanced for both test-negative and test-positive illness at baseline and that other test-negative design assumptions are met, the efficacy estimates closely match true efficacy. Analytical considerations for an odds ratio-based effect estimate arising from clustered data and potential approaches to analysis are also discussed briefly. We concluded that application of the test-negative design to certain cluster-randomized trials could increase their efficiency and ease of implementation.Entities:
Mesh:
Year: 2018 PMID: 29741576 PMCID: PMC6118074 DOI: 10.1093/aje/kwy099
Source DB: PubMed Journal: Am J Epidemiol ISSN: 0002-9262 Impact factor: 4.897